

Result for trial EudraCT 2010-021438-68.

Study title: “A randomised, double-blind, placebo-controlled, Phase IIa pilot study to evaluate the safety, tolerability and efficacy of Lytixar™ (LTX-109) in patients with uncomplicated, Gram-positive, skin infection”

Results: In trial C10-109-03/EudraCT no. 2010-021438-68 LTX-109 was applied topically TID for five days in patients with uncomplicated, gram-positive skin infections. In this study LTX-109 was shown to be safe, well-tolerated and the data indicated a beneficial effect in bacterial eradication.